Salicylic acid: Difference between revisions
No edit summary |
No edit summary |
||
(7 intermediate revisions by the same user not shown) | |||
Line 2: | Line 2: | ||
|authorTag={{Ammu}} | |authorTag={{Ammu}} | ||
|genericName=Salicylic acid | |genericName=Salicylic acid | ||
|aOrAn= | |aOrAn=an | ||
|drugClass=anti acne agent | |drugClass=anti [[acne]] agent | ||
|indicationType=treatment | |indicationType=treatment | ||
|indication=[[acne]], for relief of [[itching]], irritation, redness and scaling assoicated with [[psoriasis]], [[eczema]] and [[seborrheic dermatitis]] | |indication=[[acne]], for relief of [[itching]], irritation, [[redness]] and scaling assoicated with [[psoriasis]], [[eczema]] and [[seborrheic dermatitis]] | ||
|adverseReactions=[[hypersensitivity]] reaction, salicylate toxicity | |adverseReactions=[[hypersensitivity]] reaction, salicylate toxicity | ||
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span> | |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span> | ||
Line 17: | Line 17: | ||
|fdaLIADAdult=* FOR THE TREATMENT OF ACNE | |fdaLIADAdult=* FOR THE TREATMENT OF ACNE | ||
* HELPS KEEP SKIN CLEAR OF NEW ACNE BLEMISHES | * HELPS KEEP SKIN CLEAR OF NEW ACNE BLEMISHES | ||
* For relief of itching, irritation, redness and scaling assoicated with psoriasis, eczema and seborrheic dermatitis. | * For relief of itching, irritation, redness and scaling assoicated with [[psoriasis]], [[eczema]] and [[seborrheic dermatitis]]. | ||
|offLabelAdultGuideSupport=* Acne vulgaris | |offLabelAdultGuideSupport=* [[Acne vulgaris]] | ||
:* Apply TOPICALLY in concentrations of 0.5% to 10% | :* Apply TOPICALLY in concentrations of 0.5% to 10% | ||
Disorder of skin, Hyperkeratotic: gel, apply TOPICALLY to the affected area and occlude the area at night. | :* Disorder of skin, Hyperkeratotic: gel, apply TOPICALLY to the affected area and occlude the area at night. | ||
* Disorder of skin, Hyperkeratotic | * Disorder of skin, Hyperkeratotic | ||
:* shampoo, wet hair and apply TOPICALLY to the scalp, work into a lather and rinse; repeat the treatment as needed until the condition clears [5] | :* shampoo, wet hair and apply TOPICALLY to the scalp, work into a lather and rinse; repeat the treatment as needed until the condition clears [5] | ||
Line 181: | Line 181: | ||
* It does this not by direct inhibition of COX like most other non-steroidal anti-inflammatory drugs (NSAIDs) but instead by suppression of the expression of the enzyme (via a yet-unelucidated mechanism).<ref name=American chemical society>{{cite web | title = American chemical society | url =http://www.cas.org/news/insights/science-connections/aspirin}}</ref> | * It does this not by direct inhibition of COX like most other non-steroidal anti-inflammatory drugs (NSAIDs) but instead by suppression of the expression of the enzyme (via a yet-unelucidated mechanism).<ref name=American chemical society>{{cite web | title = American chemical society | url =http://www.cas.org/news/insights/science-connections/aspirin}}</ref> | ||
* Salicylic acid has also been shown to activate adenosine monophosphate-activated protein kinase (AMPK), and it is thought that this action may play a role in the anticancer effects of the compound and its prodrugs aspirin and salsalate. In addition, the antidiabetic effects of salicylic acid are likely mediated by AMPK activation primarily through allosteric conformational change that increases levels of phosphorylation.<ref name="pmidPMID 22517326">{{cite journal| author=Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ et al.| title=The ancient drug salicylate directly activates AMP-activated protein kinase. | journal=Science | year= 2012 | volume= 336 | issue= 6083 | pages= 918-22 | pmid=PMID 22517326 | doi=10.1126/science.1215327 | pmc=PMC3399766 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22517326 }} </ref> | * Salicylic acid has also been shown to activate adenosine monophosphate-activated protein kinase (AMPK), and it is thought that this action may play a role in the anticancer effects of the compound and its prodrugs aspirin and salsalate. In addition, the antidiabetic effects of salicylic acid are likely mediated by AMPK activation primarily through allosteric conformational change that increases levels of phosphorylation.<ref name="pmidPMID 22517326">{{cite journal| author=Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ et al.| title=The ancient drug salicylate directly activates AMP-activated protein kinase. | journal=Science | year= 2012 | volume= 336 | issue= 6083 | pages= 918-22 | pmid=PMID 22517326 | doi=10.1126/science.1215327 | pmc=PMC3399766 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22517326 }} </ref> | ||
* Salicylic acid also uncouples oxidative phosphorylation, which leads to increased ADP:ATP and AMP:ATP ratios in the cell. As a consequence, salicylic acid may alter AMPK activity and subsequently exert its anti-diabetic properties through altered energy status of the cell. Even in AMPK knock-out mice, however, there is an anti-diabetic effect, demonstrating that there is at least one additional, yet-unidentified action of the compound.<ref name= | * Salicylic acid also uncouples oxidative phosphorylation, which leads to increased ADP:ATP and AMP:ATP ratios in the cell. As a consequence, salicylic acid may alter AMPK activity and subsequently exert its anti-diabetic properties through altered energy status of the cell. Even in AMPK knock-out mice, however, there is an anti-diabetic effect, demonstrating that there is at least one additional, yet-unidentified action of the compound. | ||
<ref name=Newscientist>{{cite web | title = Newscientist | url =http://www.newscientist.com/article/dn21718-clues-to-aspirins-anticancer-effects-revealed.html }}</ref> | |||
|structure=<!--Pharmacodynamics--> | |structure=<!--Pharmacodynamics--> | ||
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label. | |PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label. | ||
Line 201: | Line 202: | ||
<!--Brand Names--> | <!--Brand Names--> | ||
|brandNames=* ALA-SEPTIC®<ref>{{Cite web | title =ALA-SEPTIC- salicylic acid cream | url =http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edb70750-bea8-4c0f-9453-f2c38d2f05d9 }}</ref> | |brandNames=* ALA-SEPTIC®<ref>{{Cite web | title =ALA-SEPTIC- salicylic acid cream | url =http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edb70750-bea8-4c0f-9453-f2c38d2f05d9 }}</ref> | ||
|drugShortage= | |drugShortage= | ||
}} | }} | ||
Line 209: | Line 207: | ||
|fileName=Saly 1.jpg | |fileName=Saly 1.jpg | ||
}} | }} | ||
{{LabelImage}} | {{LabelImage | ||
|fileName=Saly 2.png | |||
}} | |||
{{LabelImage | |||
|fileName=Saly 3.png | |||
}} | |||
{{LabelImage | |||
|fileName=Saly 4.png | |||
}} | |||
<!--Pill Image--> | <!--Pill Image--> | ||
Line 223: | Line 229: | ||
[[Category:Drug]] | [[Category:Drug]] | ||
[[Category:Non-steroidal anti-inflammatory drugs]] | |||
[[Category:Antiseptics]] |
Latest revision as of 20:28, 4 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Salicylic acid is an anti acne agent that is FDA approved for the treatment of acne, for relief of itching, irritation, redness and scaling assoicated with psoriasis, eczema and seborrheic dermatitis. Common adverse reactions include hypersensitivity reaction, salicylate toxicity.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
- FOR THE TREATMENT OF ACNE
- HELPS KEEP SKIN CLEAR OF NEW ACNE BLEMISHES
- For relief of itching, irritation, redness and scaling assoicated with psoriasis, eczema and seborrheic dermatitis.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
- Apply TOPICALLY in concentrations of 0.5% to 10%
- Disorder of skin, Hyperkeratotic: gel, apply TOPICALLY to the affected area and occlude the area at night.
- Disorder of skin, Hyperkeratotic
- shampoo, wet hair and apply TOPICALLY to the scalp, work into a lather and rinse; repeat the treatment as needed until the condition clears [5]
- Psoriasis
- Apply TOPICALLY in concentrations of 3% to 6%
- Removal of wart
- Apply TOPICALLY once or twice daily in concentrations of 5% to 40% for up to 12 weeks
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Salicylic acid in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding FDA-labeled indications and dosage information of Salicylic acid in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Salicylic acid in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Salicylic acid in pediatric patients.
Contraindications
There is limited information regarding Salicylic acid Contraindications in the drug label.
Warnings
- For external use only.
- Avoid contact with eyes. If contact occurs, rinse thoroughly with water.
- Do not use without consulting a doctor if the condition appears over a large portion of hte body.
- If condition worsens, or does not improve after using as directed, consult physician.
- Do not use for prolonged periods without consulting a doctor.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Salicylic acid in the drug label.
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Salicylic acid in the drug label.
Drug Interactions
There is limited information regarding Salicylic acid Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Salicylic acid in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Salicylic acid during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Salicylic acid with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Salicylic acid with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Salicylic acid with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Salicylic acid with respect to specific gender populations.
Race
There is no FDA guidance on the use of Salicylic acid with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Salicylic acid in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Salicylic acid in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Salicylic acid in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Salicylic acid in patients who are immunocompromised.
Administration and Monitoring
Administration
- Topical
Monitoring
There is limited information regarding Monitoring of Salicylic acid in the drug label.
IV Compatibility
There is limited information regarding IV Compatibility of Salicylic acid in the drug label.
Overdosage
There is limited information regarding Chronic Overdose of Salicylic acid in the drug label.
Pharmacology
Template:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox ECNumberTemplate:Chembox E numberTemplate:Chembox RTECSTemplate:Chembox AppearanceTemplate:Chembox OdourTemplate:Chembox DensityTemplate:Chembox MeltingPtTemplate:Chembox BoilingPtTemplate:Chembox SublimationConditionsTemplate:Chembox SolubilityInWaterTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox LogPTemplate:Chembox VaporPressureTemplate:Chembox pKaTemplate:Chembox LambdaMaxTemplate:Chembox RefractIndexTemplate:Chembox ThermochemistryTemplate:Chembox GHSPictogramsTemplate:Chembox GHSSignalWordTemplate:Chembox HPhrasesTemplate:Chembox PPhrasesTemplate:Chembox EyeHazardTemplate:Chembox SkinHazardTemplate:Chembox NFPATemplate:Chembox FlashPtTemplate:Chembox AutoignitionPtTemplate:Chembox Lethal amounts (set)Template:Chembox SupplementTemplate:Chembox header2 | Salicylic acid | |
---|---|
Identifiers | |
3D model (JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard | Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). |
KEGG | |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C7H6O3 | |
Molar mass | 138.12 g·mol−1 |
Hazards | |
Related compounds | |
Template:Chembox header2 | Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references |
Mechanism of Action
- Salicylic acid has been shown to work through several different pathways. It produces its anti-inflammatory effects via suppressing the activity of cyclooxygenase (COX), an enzyme that is responsible for the production of pro-inflammatory mediators such as the prostaglandins.
- It does this not by direct inhibition of COX like most other non-steroidal anti-inflammatory drugs (NSAIDs) but instead by suppression of the expression of the enzyme (via a yet-unelucidated mechanism).
- Salicylic acid has also been shown to activate adenosine monophosphate-activated protein kinase (AMPK), and it is thought that this action may play a role in the anticancer effects of the compound and its prodrugs aspirin and salsalate. In addition, the antidiabetic effects of salicylic acid are likely mediated by AMPK activation primarily through allosteric conformational change that increases levels of phosphorylation.[7]
- Salicylic acid also uncouples oxidative phosphorylation, which leads to increased ADP:ATP and AMP:ATP ratios in the cell. As a consequence, salicylic acid may alter AMPK activity and subsequently exert its anti-diabetic properties through altered energy status of the cell. Even in AMPK knock-out mice, however, there is an anti-diabetic effect, demonstrating that there is at least one additional, yet-unidentified action of the compound.
Structure
There is limited information regarding Salicylic acid Structure in the drug label.
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Salicylic acid in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Salicylic acid in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Salicylic acid in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Salicylic acid in the drug label.
How Supplied
There is limited information regarding Salicylic acid How Supplied in the drug label.
Storage
There is limited information regarding Salicylic acid Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Salicylic acid |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Salicylic acid |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
- Wash affected areas well with soap and water. Pat dry. Apply cream to affected area one to four times per day, or as directed by physician.
Precautions with Alcohol
- Alcohol-Salicylic acid interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- ALA-SEPTIC®[9]
Look-Alike Drug Names
There is limited information regarding Salicylic acid Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ 1.0 1.1 1.2 Template:RubberBible92nd
- ↑ 2.0 2.1 2.2 2.3 2.4 Template:PubChemLink
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 http://chemister.ru/Database/properties-en.php?dbid=1&id=1777
- ↑ 4.0 4.1 4.2 Seidell, Atherton; Linke, William F. (1952). [Google Books Solubilities of Inorganic and Organic Compounds] Check
|url=
value (help). Van Nostrand. Retrieved 2014-05-29. - ↑ Salicyclic acid. Drugbank.ca. Retrieved on 2012-06-03.
- ↑ 6.0 6.1 6.2 Template:Sigma-Aldrich
- ↑ Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ; et al. (2012). "The ancient drug salicylate directly activates AMP-activated protein kinase". Science. 336 (6083): 918–22. doi:10.1126/science.1215327. PMC 3399766. PMID 22517326 PMID 22517326 Check
|pmid=
value (help). - ↑ "Newscientist".
- ↑ "ALA-SEPTIC- salicylic acid cream".
{{#subobject:
|Label Page=Salicylic acid |Label Name=Saly 1.jpg
}}
{{#subobject:
|Label Page=Salicylic acid |Label Name=Saly 2.png
}}
{{#subobject:
|Label Page=Salicylic acid |Label Name=Saly 3.png
}}
{{#subobject:
|Label Page=Salicylic acid |Label Name=Saly 4.png
}}
- Pages with script errors
- Pages with non-numeric formatnum arguments
- Pages with reference errors
- Pages with URL errors
- CS1 errors: PMID
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- CS1 maint: PMC format
- Chemical articles with unknown parameter in Chembox
- ECHA InfoCard ID from Wikidata
- Chembox having DSD data
- Chembox having GHS data
- Drug
- Non-steroidal anti-inflammatory drugs
- Antiseptics